Additional file 1: Fig. S1. Image of PB nanoparticles. Fig. S2. FTIR spectra of PB nanoparticles, drugs (R837 and DTX), PLGA nanospheres, P-P nanospheres, P-PDR nanospheres and M@P-PDR nanospheres. Fig. S3. Standard curve of PB, R837 and DTX. Fig. S4. PA imaging intensities under full-spectrum scanning. Fig. S5. Cell viabilities of 4T1 cells after co-incubation with of M@P-PDR and P-PDR for 12 h. Fig. S6. In vivo biosafety of M@P-PDR. Fig. S7. Western blotting analysis of membrane-specific protein markers. Fig. S8. Validation Homologous Targeting Capability of M@P-PDR. (A) CLSM images of 4T1 cells, MDA-MB-231 cells or SKBR3 cells coincubated with M@P-PDR for 2h, respectively. (B) The corresponding flow cytometry quantitative analyses of intracellular uptake. Fig. S9. Confocal microscopy images of 4T1 cells treated with P-PDR and M@P-PDR. Fig. S10. (A) Fluorescence images of major organs and tumors in M@P-PDR and P-PDR treated groups 24 h after intravenous administration and (B) the corresponding fluorescence intensities. (C) In vivo PA images of tumors. (D) T1-weighted MR images of 4T1 tumor-bearing mice. Fig. S11. (A) Flow cytometric analysis of DCs maturation in distant tumors (2nd) and lymph nodes. (B) The corresponding quantification of DCs maturation in distant tumors (2nd) and (C) the corresponding quantification analysis of DCs maturation in lymph nodes (LNs). Fig. S12. (A) Immunofluorescence images of CD80 and CD206 in distant tumors (2nd) on day 9. (B) Immunofluorescence images of CD8+ T cells in the distant tumors (2nd) on day 9 after different treatments. Fig. S13. Images of mice during the 27-day treatment period. Fig. S14. (A) Statistical analysis of primary tumors (1st) and (B) distant tumors (2nd) on day 27. (C) Time-dependent body weight curves of mice. (D) Survival curves of mice after different treatments. Fig. S15. H&E staining of the major organs of all groups collected on day 3 after different treatments. Fig. S16. Time-dependent body weight curves of mice. Table S1. The comparison of photothermal/chemo-/immuno- cocktail therapy with other tumor therapeutic modalities